Strong Revenue Growth
Alvotech reported a 420% revenue growth in 2024 and is guiding approximately 20% growth for 2025. The company has experienced an average annual growth rate of 127% from 2021 to 2024 and is projecting a compounded average growth rate of 94% through 2025.
Expanding Global Market Presence
Alvotech has launched its biosimilars in the U.S., Japan, and the U.K., and expects EMA approval soon for its biosimilar to Simponi. The company continues to hold significant market shares in Europe and Canada.
Pipeline and Product Approvals
The company has 5 approved biosimilars and 12 other disclosed development programs, with cell lines for an additional 15 targets. They are targeting a market worth over $185 billion.
Strategic Investments and Acquisitions
Alvotech has invested approximately $2 billion in building a global biosimilar company and recently acquired Ivers-Lee to increase capacity for finished product assembly and packaging.